Acyclovir Dosing for Neonatal HSV Sepsis
For neonates with suspected herpes simplex virus sepsis (disseminated disease or CNS involvement), administer intravenous acyclovir at 20 mg/kg every 8 hours for 21 days. 1
Dosing Algorithm by Disease Classification
Disseminated or CNS Disease
- Dose: 20 mg/kg IV every 8 hours
- Duration: 21 days (minimum)
- Critical requirement: For CNS disease, repeat CSF HSV DNA PCR at days 19-21 of therapy; do not discontinue acyclovir until CSF PCR is negative 1
- This applies to neonates from birth to 3 months of age 2
Skin, Eye, and Mouth (SEM) Disease Only
- Dose: 20 mg/kg IV every 8 hours
- Duration: 14 days 1
- Even localized disease carries 2-6% risk of later neurologic sequelae despite treatment 2
Administration Details
Infusion rate: Administer each dose as a constant-rate infusion over 1 hour 3. Never give as rapid bolus or intramuscular/subcutaneous injection.
Maximum dose: Do not exceed 20 mg/kg every 8 hours for any patient 3
Renal adjustment: Acyclovir is primarily renally excreted; adjust dosing interval based on creatinine clearance if renal impairment develops 2
Critical Monitoring
The FDA label notes that neonatal HSV infections have been studied at 10 mg/kg, 15 mg/kg, and 20 mg/kg every 8 hours 3. However, the 20 mg/kg dose is now standard based on improved outcomes - reducing mortality to 5% in neonatal HSV encephalitis with approximately 40% of survivors developing normally 4.
Major Toxicities to Monitor:
- Neutropenia (absolute neutrophil count <1,000/mm³) - occurs in up to 46-67% of neonates on high-dose acyclovir 2
- Nephrotoxicity (Grade 3 or higher in 6% of cases) - maintain adequate hydration 2
- Phlebitis and extravasation injuries - use appropriate infusion concentrations (≤7 mg/mL recommended) 3
Common Pitfalls
Do not use the older 10 mg/kg dosing for neonatal disseminated or CNS disease. The FDA label lists 10 mg/kg for neonatal HSV 3, but this reflects older data. Multiple guidelines now recommend 20 mg/kg based on superior outcomes 2, 1, 2, 1. The 8% relapse rate seen with 10 mg/kg for 10 days versus no documented relapse with 20 mg/kg for 21 days supports this higher dosing 4.
Do not stop therapy prematurely in CNS disease. Even if clinical improvement occurs, continue until repeat CSF PCR is negative at day 19-21 1. This prevents relapse, which can occur in up to 26-29% of inadequately treated pediatric cases 5.
Do not use oral acyclovir for acute neonatal disease. Oral preparations do not achieve adequate CSF levels and are only appropriate for suppressive therapy after completing IV treatment 2.
Post-Treatment Considerations
After completing the initial 14-21 day IV course, some experts recommend oral acyclovir suppressive therapy (300 mg/m² body surface area 2-3 times daily) to reduce recurrent skin lesions and potentially improve neurodevelopmental outcomes 2. However, this carries a 46% risk of neutropenia, though usually self-limited 2.